Weekly Recap: Q3 loss, cash runway and Gemini study CRO selection

Revelation Biosciences, Inc. (NASDAQ:REVB) reported a third-quarter 2026 net loss of $3.3 million, or $5.92 per share, and no revenue; cash fell to $9.1 million, expected to last into the second quarter of 2027. The company selected a contract research organization for its planned Gemini study in acute kidney injury.

Previous Week Recap

• Q3 Loss And Cash Runway: REVB reported a $3.3 million third-quarter 2026 net loss, or $5.92 per share, with no revenue. Cash fell to $9.1 million by Sept. 30; funds are expected to last into Q2 2027.
  • 
  • 
  • 
  3 источника
• CRO Selected For Gemini Study: Revelation Biosciences, Inc. (REVB) selected a contract research organization for its planned Gemini study in acute kidney injury and incurred related preparation costs during the quarter.
  • 
  Reuters